Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to improve lymphoma treatment

NCT ID NCT06425302

Disease control Sponsor: Celgene Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a new combination of drugs, golcadomide and rituximab, in 90 people with newly diagnosed advanced follicular lymphoma. The goal is to see if this combination can improve complete remission rates compared to standard treatments. The study is active but no longer recruiting participants.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
golcadomide (a drug) combined with rituximab (a drug)
What this could lead to
If successful, this combination could offer a new first-line treatment option for advanced follicular lymphoma, potentially improving remission rates.
What could go wrong
This is a phase 2 trial with only 90 participants, so results are preliminary. The combination may not prove more effective than standard treatments, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

95 people

The number who actually took part.

Started

Aug 2024

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Participant has histologically confirmed Grade 1, 2 or 3a follicular lymphoma (FL) or classic FL. Formalin-fixed paraffin embedded (FFPE) archival tissue from 1 year prior to screening is allowed. If more than 1 year has passed, then a fresh biopsy must be obtained to confirm the diagnosis. * Have no prior systemic treatment for follicular lymphoma. Prior radiation therapy or surgery for previously diagnosed stage I disease is acceptable. * Stage II to IV disease. * Deemed to need treatment by treating investigator. Reasons for treatment can include, but are not limited to, the following:. i) Bulky disease defined as:. A. A nodal or extra nodal (except spleen) mass \> 7cm in its greater diameter or, involvement of at least 3 nodal or extra nodal sites (each with a diameter greater than \>3 cm). ii) Presence of at least one of the following B symptoms:. A. Fever (\>38°C) of unclear etiology. B. Night sweats. C. Weight loss greater than 10% within the prior 6 months. iii) Splenomegaly with inferior margin below the umbilical line. iv) Any one of the following cytopenia due to lymphoma:. A. Platelets \<100,000 cells/mm3 (100 x 109/L). B. Absolute neutrophil count (ANC) \< 1,000 cells/mm3 (1.0 x 109/L). C. Hemoglobin \< 10g/dL (6.25 mmol/L). v) Pleural or peritoneal serous effusion (irrespective of cell content). vi) Any compressive syndrome (for example, but not restricted to ureteral, orbital, gastrointestinal). Exclusion Criteria * Clinical evidence of transformed lymphoma by investigator assessment. * Follicular Large Cell as per WHO 5th classification or Grade 3b follicular lymphoma as per WHO 4th classification. * Participant has any significant medical condition, active infection, laboratory abnormality, or psychiatric illness that would prevent the participation in the study. * Other protocol-defined Inclusion/Exclusion criteria apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lymphoma, follicular are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

follicular lymphoma lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymphoma, follicular

Contacts and locations

Locations

  • Local Institution - 0005

    Jacksonville, Florida, 32224, United States

  • Local Institution - 0019

    Westwood, Kansas, 66205, United States

  • Local Institution - 0022

    Washington D.C., District of Columbia, 20007, United States

  • Local Institution - 0026

    Tampa, Florida, 33606, United States

  • Local Institution - 0031

    Rochester, Minnesota, 55905, United States

  • Local Institution - 0035

    San Francisco, California, 94143, United States

  • Local Institution - 0046

    Liverpool, New South Wales, 2170, Australia

  • Local Institution - 0049

    Santiago, Santiago Metropolitan, 7500921, Chile

  • Local Institution - 0050

    Santiago, Santiago Metropolitan, 7580206, Chile

  • Local Institution - 0052

    Salt Lake City, Utah, 84106, United States

  • Local Institution - 0055

    Anchorage, Alaska, 99508, United States

  • Local Institution - 0056

    São Paulo, 05652-900, Brazil

  • Local Institution - 0058

    São Paulo, 04543-000, Brazil

  • Local Institution - 0060

    Rio de Janeiro, 22250-905, Brazil

  • Local Institution - 0061

    Porto Alegre, Rio Grande do Sul, 90035-903, Brazil

  • Local Institution - 0064

    Toronto, Ontario, M5G 2M9, Canada

  • Local Institution - 0070

    South Brisbane, Queensland, 4101, Australia

  • Local Institution - 0075

    Naples, 80131, Italy

  • Local Institution - 0076

    Bologna, 40138, Italy

  • Local Institution - 0085

    Seoul, Seoul-teukbyeolsi [Seoul], 03080, South Korea

  • Local Institution - 0086

    Seoul, Seoul-teukbyeolsi [Seoul], 06351, South Korea

  • Local Institution - 0092

    Kaohsiung City, 83301, Taiwan

  • Local Institution - 0094

    Kaohsiung City, 807, Taiwan

  • Local Institution - 0100

    Busan, Pusan-Kwangyǒkshi, 49241, South Korea

  • Local Institution - 0101

    Saint-Cloud, Hauts-de-Seine, 92210, France

  • Local Institution - 0103

    Lille, Nord, 59000, France

  • Local Institution - 0105

    Nottingham, NG5 1PB, United Kingdom

  • Local Institution - 0111

    Henderson, Nevada, 89074, United States

  • Local Institution - 0112

    Canterbury, Kent, CT1 3NG, United Kingdom

  • Local Institution - 0115

    Edinburgh, Midlothian, EH4 2XU, United Kingdom

  • Local Institution - 0118

    Paris, 75010, France

  • Local Institution - 0121

    Poitiers, Vienne, 86021, France

  • Local Institution - 0123

    Taipei, 10002, Taiwan

  • Local Institution - 0152

    Birmingham, Alabama, 35294-3300, United States

  • Local Institution - 0175

    Southampton, Hampshire, SO16 0YD, United Kingdom

  • Local Institution - 0179

    Rozzano, Milano, 20089, Italy

  • Local Institution - 0180

    Phoenix, Arizona, 85054, United States

  • Local Institution - 0181

    Traralgon, Victoria, 3844, Australia

  • Local Institution - 0183

    Hackensack, New Jersey, 07601, United States

  • Local Institution - 0185

    Warsaw, Masovian Voivodeship, 01-748, Poland

  • Local Institution - 0186

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-168, Poland

  • Local Institution - 0187

    Skórzewo, Greater Poland Voivodeship, 60-185, Poland

  • Local Institution - 0188

    Chemnitz, Saxony, 09116, Germany

  • Local Institution - 0189

    Dresden, 01307, Germany

  • Local Institution - 0190

    Tucson, Arizona, 85711, United States

  • Local Institution - 0191

    Madrid, 28040, Spain

  • Local Institution - 0192

    Valencia, Valenciana, Comunitat, 46017, Spain

  • Local Institution - 0196

    Palma, Balears [Baleares], 07120, Spain

  • Local Institution - 0197

    Regensburg, Bavaria, 93049, Germany

  • Local Institution - 0198

    Rome, Lazio, 00133, Italy

  • Local Institution - 0201

    Norfolk, Virginia, 23502, United States

  • Local Institution - 0202

    Seattle, Washington, 98109, United States

  • Local Institution - 0205

    Chicoutimi, Quebec, G7H 5H6, Canada

  • Local Institution - 0208

    West Palm Beach, Florida, 33401, United States

  • Local Institution - 0209

    Fort Myers, Florida, 33901, United States

  • Local Institution - 0210

    St. Petersburg, Florida, 33705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.